Together we will beat cancer

Donate

Lung cancer is the third most common cancer in the UK, with around 48,500 people diagnosed each year. There are two main types of lung cancer – small cell lung cancer and non small cell lung cancer – depending on how the cells look under the microscope.

The main symptoms are a cough, shortness of breath and weight loss.

Four new cancer drugs approved on NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved 4 new cancer drugs for use on the NHS in Scotland to treat some lung, breast and prostate cancers.

Read More

Lung cancer risks becoming ‘forgotten disease’ of the coronavirus pandemic  

At least 14,000 fewer people have been urgently referred for lung cancer tests since March. 

Read More

Targeted drug for lung cancer approved for NHS use in England

The National Institute for Health and Care Excellence has approved the drug osimertinib to treat some adults in England with untreated, advanced lung cancer.

Read More

US lung cancer data points to the power of cancer research

New data suggest that targeted therapy seems to be having an impact on the treatment of lung cancer.

Read More

Pursuing precision medicine in a flagship lung cancer trial

The National Lung Matrix Trial – a £25 million collaboration with pharmaceutical companies and the NHS – has been exploring how patients with non small cell lung cancer respond to more tailored, targeted treatments.

Read More

Cancer blood test uses ‘noise cancellation’ to improve sensitivity

Cancer Research UK scientists have developed a new way to analyse blood for evidence of cancer that could be up to ten times more sensitive than previous methods.

Read More

Immunotherapy treatment recommended for advanced small cell lung cancer 

A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.

Read More

Moves and countermoves: How the immune system responds to lung cancer’s ‘tactics’

Scientists working on the TRACERx project have mapped how the immune systems responds to lung tumours over time

Read More

The power of philanthropy: TRACERx

In the first of a new blog series on the power of philanthropy, we look at TRACERx – the first longitudinal, large-scale study of lung cancer evolution.

Read More

Three new treatment options approved for NHS use in Scotland

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

Read More